Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells

Nature Medicine

Volumn 4, Issue 12, 1998, Pages 1377-1382

  Desbarats, Julie ^a   Duke, Richard C ^b   Newell, M Karen ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FAS LIGAND; INTERLEUKIN 2;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CYTOKINE PRODUCTION; GENE EXPRESSION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD95; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELLS, CULTURED; FAS LIGAND PROTEIN; INTERLEUKIN-2; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0031727680     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/3965     Document Type: Article

References (41)

1. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
2. Suda, T. et al. Expression of the Fas ligand in cells of the T lineage. J. Immunol. 154, 3806-3813 (1995).
3. Hahne, M. et al. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26, 721-724 (1996).
4. Saas, P. et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain. J. Clin. Invest. 99, 1173-1178 (1997).
5. Arase, H., Arase, N. & Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181, 1235-1238 (1995).
6. Ju, S.T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 345-348 (1995).
7. Dhein, J., Walczak, H., Baumler, C., Debatin, K.-M. & Krammer, P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-440 (1995).
8. Brunner, T. et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 342-345 (1995).
9. Renno, T., Hahne, M., Tschopp, J. & MacDonald, H.R. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J. Exp. Med. 183, 431-437 (1996).
10. Kimura, M. & Matsuzawa, A. Autoimmunity in mice bearing Ipr.cg: a novel mutant gene. Int. Rev. Immunol. 11, 193-210 (1994).
11. Hahne, M. et al. Characterization of the non-functional Fas ligand of gld mice. Int. Immunol. 7, 1381-1386 (1995).
12. Chervonsky, A.V. et al. The role of Fas in autoimmune diabetes. Cell 89, 17-24 (1997).
13. Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential role of the Fas ligand in the development of hepatitis. Nature Med. 3, 409-413 (1997).
14. Giordano, C. et al. Potential Involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960-963 (1997).
15. Itoh, N. et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186, 613-618 (1997).
16. Hahne, M. et al. Melanoma cell expression of Fas(Apo-a/CD95) Ligand: Implications for tumor immune escape. Science 274, 1363-1366 (1996).
17. O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082 (1996).
18. Niehans, G.A. et al. Human lung carcinomas express Fas ligand. Cancer Res. 57, 1007-1012 (1997).
19. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317-322 (1996).
20. Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. Anti-tumor effect of locally produced CD95L. Nature Med. 3, 165-170 (1997).
21. Arai, H., Chan, S.Y., Bishop, D.K. & Nabel, G.J. Inhibition of the alloantibody response by CD95 ligand. Nature Med. 3, 843-848 (1997).
22. Corry, D.B., Reiner, S.L., Linsley, P.S. & Locksley, R.M. Differential Effects of Blockade of CD28-B7 on the Development of Th1 or Th2 Effector Cells in Experimental Leishmaniasis. J. Immunol. 153, 4142-4148 (1994).
23. Kaneko, S., Suzuki, N., Koizumi, H., Yamamoto, S. & Sakane, T. Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin. Exp. Immunol. 109, 185-193 (1997).
24. Dou, Q.P., An, B., Antoku, K. & Johnson, D.E. Fas stimulation induces RB de-phosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell. Biochem. 64, 586-594 (1997).
25. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A. & Nagata, S. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
26. Chu, J.L. et al. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J. Exp. Med. 181, 393-398 (1995).
27. Herman, A., Kappler, J., Marrack, P. & Pullen, A.M. Superantigens: Mechanisms of T-Cell Stimulation and Role in Immune Responses. Ann. Rev. Immunol. 9, 745-772 (1991).
28. Jardetzky, T.S. et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368, 711-718 (1994).
29. Krummel, M.F. & Allison, J.P. CTLA-4 Engagement Inhibits IL-2 Accumulation and Cell-cycle Progression upon Activation of Resting T cells. J. Exp. Med. 183, 2533-2540 (1996).
30. Krummel, M.F. & Allison, J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-463 (1995).
31. Walunas, T.L., Bakker, C.Y. & Bluestone, J.A. CTLA-4 Ligation Blocks CD28-dependentT Cell Activation. J. Exp. Med. 183, 2541-2550 (1996).
32. Suzuki, I. & Fink, P.J. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas Ligand. J. Exp. Med. 187, 123-128 (1998).
33. Hutchings, P. et al. The regulation of autoimmunity through CD4+ T cells. Autoimmunity 15, 21-23 (1993).
34. Chandler, C. & Passaro, E., Jr. Transplant Rejection. Mechanisms and treatment. Arch. Surgery 128, 279-283 (1993).
35. Prud'homme, G.J. & Vanier, L.E. Cyclosporine, tolerance, and autoimmunity. Clin. Immunol. Immunopathol. 66, 185-192 (1993).
36. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
37. Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947 (1997).
38. Seino, K., Kayagaki, N., Fukao, K., Okumura, K. & Yagita, H. Rejection of Fas ligand-expressing grafts. Transplant. Proc. 29, 1092-1093 (1997).
39. Kang, S.-M. et al. Fas ligand expression in islet of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738-743 (1997).
40. Lau, H.T. & Stoeckert, C.J. FasL - Too much of a good thing? Nature Med. 3, 727-728 (1997).
41. Gillis, S. & Smith, K.A. Long term culture of tumor-specific cytotoxic T cells. Nature 268, 154-156 (1997).